These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 31471396)
41. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Roh MH; Yassin Y; Miron A; Mehra KK; Mehrad M; Monte NM; Mutter GL; Nucci MR; Ning G; Mckeon FD; Hirsch MS; Wa X; Crum CP Mod Pathol; 2010 Oct; 23(10):1316-24. PubMed ID: 20562848 [TBL] [Abstract][Full Text] [Related]
42. Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors. Aisagbonhi O; Ghlichloo I; Hong DS; Roma A; Fadare O; Eskander R; Saenz C; Fisch KM; Song W Gynecol Oncol; 2024 Aug; 187():241-248. PubMed ID: 38833993 [TBL] [Abstract][Full Text] [Related]
43. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts. McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642 [TBL] [Abstract][Full Text] [Related]
44. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Kuhn E; Meeker A; Wang TL; Sehdev AS; Kurman RJ; Shih IeM Am J Surg Pathol; 2010 Jun; 34(6):829-36. PubMed ID: 20431479 [TBL] [Abstract][Full Text] [Related]
45. The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. Kuhn E; Kurman RJ; Soslow RA; Han G; Sehdev AS; Morin PJ; Wang TL; Shih IeM Am J Surg Pathol; 2012 Dec; 36(12):1826-34. PubMed ID: 22892598 [TBL] [Abstract][Full Text] [Related]
46. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
47. Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma. Lai J; Tong C; Chien JR Anticancer Res; 2021 Sep; 41(9):4417-4422. PubMed ID: 34475063 [TBL] [Abstract][Full Text] [Related]
48. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium. Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696 [TBL] [Abstract][Full Text] [Related]
49. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors]. Wen J; Shi JL; Shen DH; Chen YX; Song QJ Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451 [TBL] [Abstract][Full Text] [Related]
50. Wilms tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Hashi A; Yuminamochi T; Murata S; Iwamoto H; Honda T; Hoshi K Int J Gynecol Pathol; 2003 Oct; 22(4):374-7. PubMed ID: 14501819 [TBL] [Abstract][Full Text] [Related]
51. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study. Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180 [TBL] [Abstract][Full Text] [Related]
52. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer. Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925 [TBL] [Abstract][Full Text] [Related]
53. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma]. Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931 [TBL] [Abstract][Full Text] [Related]
54. Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants. Ronchi S; Facchi S; Di Lauro E; Libera L; Carnevali IW; Zefiro F; Alexandrova E; Rizzo F; Sessa F; Tibiletti MG Pathol Res Pract; 2024 Mar; 255():155183. PubMed ID: 38364651 [TBL] [Abstract][Full Text] [Related]
55. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Ducie J; Dao F; Considine M; Olvera N; Shaw PA; Kurman RJ; Shih IM; Soslow RA; Cope L; Levine DA Nat Commun; 2017 Oct; 8(1):990. PubMed ID: 29042553 [TBL] [Abstract][Full Text] [Related]
56. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma. Zarei S; Wang Y; Jenkins SM; Voss JS; Kerr SE; Bell DA Am J Surg Pathol; 2020 Mar; 44(3):316-328. PubMed ID: 31876585 [TBL] [Abstract][Full Text] [Related]
57. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G Cells; 2019 Jun; 8(6):. PubMed ID: 31197119 [TBL] [Abstract][Full Text] [Related]
58. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma]. Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294 [No Abstract] [Full Text] [Related]
59. Cardiophrenic Lymph Node Metastasis of Ovarian High-grade Serous Carcinoma Showing Wild-type p53 Immunostaining Pattern and Aberrant CD56 Expression. Kwon HJ; Oh M; Han J; Song SY; Kim HS Int J Surg Pathol; 2021 Dec; 29(8):864-869. PubMed ID: 33764173 [TBL] [Abstract][Full Text] [Related]
60. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]